东方生物：预计2025年年度归母净利润亏损5.23亿元

Core Viewpoint - The company, Dongfang Biological, is expected to report a net loss attributable to shareholders of the parent company amounting to 523 million yuan for the fiscal year 2025, indicating a challenging financial outlook [1] Financial Performance Summary - The projected net profit attributable to shareholders of the parent company for 2025 is -523 million yuan, with a net profit excluding non-recurring gains and losses of -558 million yuan [1] - In the same period last year, the total profit was -585 million yuan, with a net profit attributable to shareholders of the parent company at -529 million yuan, and a net profit excluding non-recurring gains and losses of -571 million yuan [1] - The earnings per share for the previous year was reported at -2.69 yuan [1]